Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A new role of SNAI2 in postlactational involution of the mammary gland links it to luminal breast cancer development

  • Castillo, Sonia
  • Hontecillas-Prieto, Lourdes
  • Blanco-Gómez, Adrián
  • Sáez-Freire, María del Mar
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Pérez-Andrés, Martin
  • Orfao, Alberto
  • Cañamero, Marta
  • Mao, Jian-Hua
  • Gridley, Thomas
  • Castellanos-Martín, Andrés
  • Pérez-Losada, J.
PMCID: PMC4560637, Breast cancer is a major cause of mortality in women. The transcription factor SNAI2 has been implicated in the pathogenesis of several types of cancer, including breast cancer of basal origin. Here we show that SNAI2 is also important in the development of breast cancer of luminal origin in MMTV-ErbB2 mice. SNAI2 deficiency leads to longer latency and fewer luminal tumors, both of these being characteristics of pretumoral origin. These effects were associated with reduced proliferation and a decreased ability to generate mammospheres in normal mammary glands. However, the capacity to metastasize was not modified. Under conditions of increased ERBB2 oncogenic activity after pregnancy plus SNAI2 deficiency, both pretumoral defects - latency and tumor load - were compensated. However, the incidence of lung metastases was dramatically reduced. Furthermore, SNAI2 was required for proper postlactational involution of the breast. At 3 days post lactational involution, the mammary glands of Snai2-deficient mice exhibited lower levels of pSTAT3 and higher levels of pAKT1, resulting in decreased apoptosis. Abundant noninvoluted ducts were still present at 30 days post lactation, with a greater number of residual ERBB2+ cells. These results suggest that this defect in involution leads to an increase in the number of susceptible target cells for transformation, to the recovery of the capacity to generate mammospheres and to an increase in the number of tumors. Our work demonstrates the participation of SNAI2 in the pathogenesis of luminal breast cancer, and reveals an unexpected connection between the processes of postlactational involution and breast tumorigenesis in Snai2-null mutant mice., JPL was partially supported by FEDER and MICINN (PLE2009-119, SAF2014-56989-R), Instituto de Salud Carlos III (PI07/0057, PI10/00328, PIE14/00066), Junta de Castilla y León (SAN673/SA26/08, SAN126/SA66/09, SA078A09, CSI034U13), the “Fundación Eugenio Rodríguez Pascual”, the “Fundación Inbiomed” (Instituto Oncológico Obra Social de la Caja Guipozcoa-San Sebastian, Kutxa), and the “Fundación Sandra Ibarra de Solidaridad frente al Cáncer”. AC was supported by FIS (PI07/0057) and MICINN (PLE2009-119). SCLL was funded by a JAEdoc Fellowship (CSIC)/FSE. MMSF and ABG are funded by fellowships from the Junta de Castilla y Leon. JHM was supported by the National Institutes of Health, a National Cancer Institute grant (R01 CA116481), and the Low-Dose Scientific Focus Area, Office of Biological & Environmental Research, US Department of Energy (DE-AC02-05CH11231)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients

  • Mao, Jian-Hua
  • Diest, Paul J. van
  • Pérez-Losada, J.
  • Snijders, Antoine M.
Adjuvant radiotherapy (RT) in breast cancer (BC) is often used to eradicate remaining tumor cells following surgery with the goal of maximizing local control and increasing overall survival. The current study investigated the impact of age and BC molecular subtype on overall survival after RT using a meta-analysis of the METABRIC and TCGA BC patient cohorts. We found that RT significantly prolonged survival across the whole BC patient population. The survival benefit of RT was predominantly observed in stage II BC patients treated with breast conserving surgery. Patients were then stratified by age and molecular subtype to investigate survival rate associated with RT. An increase in survival for the luminal-A and basal BC molecular subtypes was observed after RT. Stratifying patients based on age revealed that increased survival was restricted to younger patients (≤60 years of age at diagnosis). There was a significant survival benefit of radiotherapy for younger patients with tumors of the luminal A and basal molecular subtypes. Patients with other breast tumor subtypes or older breast cancer patients did not seem to benefit effects of RT. Therefore, alternate local treatment strategies should be considered for older, luminal B, and HER2 driven BC patients., A.M.S. and J.H.M were supported by Lawrence Berkeley National Laboratory Directed Research and Development (LDRD) program funding under contract DE AC02-05CH11231. J.P.L. laboratory is partially funded by FEDER and MICINN (SAF2014-56989-R), Instituto de Salud Carlos III (PIE14/00066), Junta de Castilla y León (CSI001416), IBSAL (IBY15/00003)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma

  • Cañueto, Javier
  • Cardeñoso-Álvarez, Ester
  • García, Juan L.
  • Santos-Briz, Ángel
  • Castellanos-Martín, Andrés
  • Fernández-López, Emilia
  • Blanco-Gómez, Adrián
  • Pérez-Losada, J.
  • Román-Curto, Concépción
[Background]: Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans after basal cell carcinoma, and its incidence is dramatically rising. CSCC is rarely problematic, but given its high frequency, the absolute number of complicated cases is also high. It is necessary to identify molecular markers in order to recognize those CSCCs with poor prognosis. There is controversy concerning the role of epidermal growth factor receptor (EGFR) as a marker of prognosis in CSCC. In addition, EGFR-targeted therapies have emerged in recent years and a better understanding of the role of EGFR in CSCC may be of help for some patients in predicting prognosis and guiding curative management. [Objectives]: To evaluate the role of EGFR as a prognostic factor in CSCC. [Methods]: We evaluated clinical and histopathological features, including events of poor clinical evolution, in a series of 94 cases of CSCC. We also analysed EGFR expression by immunohistochemistry, fluorescent in situ hybridization and quantitative polymerase chain reaction. [Results]: We detected EGFR in 85 cases (90%), with overexpression in 33 cases (35%), and aberrant EGFR expression in the cytoplasm in 50 cases (53%). EGFR overexpression in the primary tumours was associated with lymph node progression, tumour–nodes–metastasis stage progression and proliferation (Ki-67 staining) in CSCC. EGFR overexpression and poor grade of differentiation were the strongest independent variables defining lymph node metastasis and progression in CSCC in a logistic regression model. [Conclusions]: We demonstrate that EGFR overexpression has prognostic implications associated with lymph node metastasis and progression in CSCC., J.P.‐L. was partially supported by FEDER and MICINN (PLE2009‐119, SAF2014‐56989‐R), Instituto de Salud Carlos III (PI07/0057, PI10/00328, PIE14/00066), Junta de Castilla y León (SAN673/SA26/08, SAN126/SA66/09, SA078A09, CSI034U13, BIO/SA31/15), IBSAL (IBY15/00003), the ‘Eugenio Rodríguez Pascual’, the ‘Fundación Inbiomed’ (Instituto Oncológico Obra Social de la Caja Guipozcoa‐San Sebastian, Kutxa) and the ‘Fundación Sandra Ibarra de Solidaridad frente al Cáncer’. C.R.‐C. is funded by Q3718001E (2009‐2010) and GRS 612/A/11 (2011‐2012) and ‘the Fundación Eugenio Rodríguez Pascual’. A.C.‐M. was supported by FIS (PI07/0057) and MICINN (PLE2009‐119)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The biological age linked to oxidative stress modifies breast cancer aggressiveness

  • Sáez-Freire, María del Mar
  • Blanco-Gómez, Adrián
  • Castillo, Sonia
  • Gómez-Vecino, Aurora
  • Galvis-Jiménez, Julie Milena
  • Martín-Seisdedos, Carmen
  • Isidoro-García, María
  • Hontecillas-Prieto, Lourdes
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Patino-Alonso, María Carmen
  • Galindo-Villardón, Purificación
  • Mao, Jian-Hua
  • Prieto, Carlos
  • Castellanos-Martín, Andrés
  • Kaderali, Lars
  • Pérez-Losada, J.
The incidence of breast cancer increases with age until menopause, and breast cancer is more aggressive in younger women. The existence of epidemiological links between breast cancer and aging indicates that both processes share some common mechanisms of development. Oxidative stress is associated with both cancer susceptibility and aging. Here we observed that ERBB2-positive breast cancer, which developed in genetically heterogeneous ERBB2-positive transgenic mice generated by a backcross, is more aggressive in chronologically younger than in older mice (differentiated by the median survival of the cohort that was 79 weeks), similar to what occurs in humans. In this cohort, we estimated the oxidative biological age using a mathematical model that integrated several subphenotypes directly or indirectly related to oxidative stress. The model selected the serum levels of HDL-cholesterol and magnesium and total AKT1 and glutathione concentrations in the liver. The grade of aging was calculated as the difference between the predicted biological age and the chronological age. This comparison permitted the identification of biologically younger and older mice compared with their chronological age. Interestingly, biologically older mice developed more aggressive breast cancer than the biologically younger mice. Genomic regions on chromosomes 2 and 15 linked to the grade of oxidative aging were identified. The levels of expression of Zbp1 located on chromosome 2, a gene related to necroptosis and inflammation, positively correlated with the grade of aging and tumour aggressiveness. Moreover, the pattern of gene expression of genes linked to the inflammation and the response to infection pathways was enriched in the livers of biologically old mice. This study shows part of the complex interactions between breast cancer and aging., JPL was partially supported by FEDER and the MICINN (SAF2014-56989-R and SAF2017-88854R), the Instituto de Salud Carlos III (PIE14/00066), >Proyectos Integrados IBSAL 2015> (IBY15/00003), the Sandra Ibarra Foundation >de Solidaridad Frente al Cáncer> Foundation and >We can be heroes> Foundation. JHM was supported by the National Institutes of Health, a National Cancer Institute grant (R01 CA116481), and the Low-Dose Scientific Focus Area, Office of Biological & Environmental Research, US Department of Energy (DE-AC02-05CH11231)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Supplementary data for the biological age linked to oxidative stress modifies breast cancer aggressiveness

  • Sáez-Freire, María del Mar
  • Blanco-Gómez, Adrián
  • Castillo, Sonia
  • Gómez-Vecino, Aurora
  • Galvis-Jiménez, Julie Milena
  • Martín-Seisdedos, Carmen
  • Isidoro-García, María
  • Hontecillas-Prieto, Lourdes
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Patino-Alonso, María Carmen
  • Galindo-Villardón, Purificación
  • Mao, Jian-Hua
  • Prieto, Carlos
  • Castellanos-Martín, Andrés
  • Kaderali, Lars
  • Pérez-Losada, J.
The data presented in this article are related to the research paper entitled “The biological age linked to oxidative stress modifies breast cancer aggressiveness” (M.M. Sáez-Freire, A. Blanco-Gómez, S. Castillo-Lluva, A. Gómez-Vecino, J.M. Galvis-Jiménez, C. Martín-Seisdedos, M. Isidoro-García, L. Hontecillas-Prieto, M.B. García-Cenador, F.J. García-Criado, M.C. Patino-Alonso, P. Galindo-Villardón, J.H. Mao, C. Prieto, A. Castellanos-Martín, L. Kaderali, J. Pérez-Losada). The data shown were obtained from a population of transgenic mice, MMTV-Erbb2/Neu, with different susceptibility to breast cancer and a mixed genetic background generated by backcrossing. It was observed that the aggressiveness of breast cancer negatively correlates with age, being lower in chronologically old mice, similar to what occurs in humans. Given that oxidative stress is associated with tumour susceptibility and the degree of aging, the association between the aggressiveness of breast cancer and multiple intermediate phenotypes directly or indirectly related to oxidative stress was studied. Using a mathematical model, we defined biological age and the degree of aging as the difference between biological and chronological ages. As a result, we observed that biologically old mice predominated among those that developed the disease early on, that is, those that were chronologically young. We then identified the specific and common genetic components of Quantitative Trait loci or QTL associated with different evolution of breast cancer, the intermediate phenotypes related to oxidative stress studied, the biological age and the degree of aging. Lastly, we showed that the expression pattern in the livers of biologically old mice were enriched in signalling pathways related to inflammation and response to infections; whereas the biologically young mice exhibited enriched pathways related to mitochondrial activity. For the explanation and discussion of these data refer to the research article cited above., JPL was partially supported by FEDER and the MICINN (SAF2014-56989-R, SAF2017-88854R), the Instituto de Salud Carlos III (PIE14/00066), >Proyectos Integrados IBSAL 2015> (IBY15/00003), the Sandra Ibarra Foundation>de Solidaridad Frente al Cáncer> Foundation and >We can be heroes> Foundation. JHM was supported by the National Institutes of Health, a National Cancer Institute grant (R01 CA116481), and the Low-Dose Scientific Focus Area, Office of Biological & Environmental Research, US Department of Energy (DE-AC02−05CH11231)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis doctoral (DoctoralThesis)

Identificación de determinantes genéticos y moleculares de la evolución y la respuesta a la quimioterapia del cáncer de mama mediante el análisis de fenotipos intermedios

  • Blanco-Gómez, Adrián
Trabajo presentado por el doctorando D. Adrián Blanco Gómez, que ha sido realizado en el Instituto de Biología Molecular y Celular del Cáncer de Salamanca, para optar al Título de Doctor por la Universidad de Salamanca., El cáncer de mama es una enfermedad de génesis compleja, con un componente de genética cuantitativa que contribuye a la variabilidad en la susceptibilidad y en la evolución de la enfermedad entre individuos. La distinta respuesta a la quimioterapia entre pacientes con aparentemente la misma enfermedad es el resultado de diferencias en interacciones entre múltiples fenotipos intermedios que participan en el proceso patogénico del cáncer de mama. Muy a menudo, cada uno de estos fenotipos intermedios es a su vez un rasgo complejo que sigue un patrón de herencia de genética cuantiativa. En este trabajo, proponemos que el análisis de estos fenotipos intermedios podría ser una estrategia para explicar parte de la variabilidad en la evolución del cáncer de mama en presencia de quimioterapia y sin ella. Con este objetivo, hemos estudiado diferentes aspectos de la evolución tumoral sin tratamiento, y en respuesta a docetaxel y doxorrubicina, en poblaciones de ratones genéticamente heterogéneas con cáncer de mama HER2 positivo. A continuación, analizamos varios fenotipos de la biología tumoral como la presencia de distintas mutaciones oncogénicas, la longitud telomérica tumoral, la actividad de varias vías de señalización tumorales, la composición celular del tumor y su índice proliferativo. Hemos encontrado numerosas asociaciones entre estos parámetros tumorales y la evolución clínica de la enfermedad que sugieren que estos parámetros tumorales pudieron contribuir a la heterogeneidad en la evolución clínica observada en los ratones estudiados. Finalmente, hemos identificado un número de regiones genómicas donde las diferencias en el genotipo se asociaron con diferencias en la evolución clínica del tumor y en los fenotipos tumorales intermedios estudiados. Todas estas regiones podrían contener determinantes genéticos de la evolución del cáncer de mama sin tratamiento y de la respuesta a la quimioterapia con docetaxel y doxorrubicina., La investigación en nuestro laboratorio ha estado financiada por el Fondo Europeo de Desarrollo Regional (FEDER), el Ministerio de Economía y Competitividad (MICINN) (PLE2009-119, SAF2014-56989-R), el Instituto de Salud Carlos III (PI07/0057, PI10/00328, PIE14/00066), Junta de Castilla y León (CSI034U13, BIO/SA31/15), "Proyectos Integrados IBSAL 2015" (IBY15/00003) y la “Fundación Sandra Ibarra de Solidaridad frente al Cáncer”. Durante el transcurso de este trabajo, he sido beneficiario de una ayuda destinada a financiar la contratación predoctoral de personal investigador de la Junta de Castilla y León cofinanciada por el Fondo Social Europeo (ORDEN EDU/1084/2012); y de una beca con cargo a la investigación (Contrato Art.83 LOU (GRIFOLS-USAL)) con referencia LBNL y de un contrato para titulado superior financiado por la asociación “We Can Be Heroes”., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Identification of genetic and molecular determinants associated with cardiotoxicity by anthracyclines and taxanes according to age

  • Gómez-Vecino, Aurora
  • Corchado Cobos, Roberto
  • Blanco-Gómez, Adrián
  • Prieto, Carlos
  • Patino-Alonso, María Carmen
  • Galindo, P.
  • Fraile, Susana
  • Rodrigues Teixeira, Telmo
  • García-Macías, Carmen
  • Galvis-Jiménez, Julie Milena
  • García Sánchez, Asunción
  • Isidoro-García, María
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • García-Sancha, Natalia
  • Holgado-Madruga, Marina
  • Sánchez-Fernández, Pedro Luis
  • Pérez-Losada, J.
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]: Cardiotoxicity due to anthracyclines (CDA) is a very common problem in cancer patients, with great repercussion on their quality of life, which limits chemotherapy treatment and has consequences in the final prognosis of the oncologic disease itself. The susceptibility and degree of cardiotoxicity by anthracyclines is very heterogeneous among patients, and who will suffer this complication is unknown. CDA is a complex trait, thus follows a model of quantitative genetics, whose polygenic component is mostly unidentified. In addition, as a complex trait, CDA heterogeneity is explained by the variability among subphenotypes that would participate in its pathogenesis. Thus, anthracyclines exert their toxicity through DNA damage, so that among these subphenotypes would be the molecular pathways involved in the response to it, and a series of signaling pathways that promote and others that protect from that heart damage anthracyclines have a pro-genotoxicity effect. Differences in these pathways with the genetic variants linked with them could contribute to different susceptibility to CDA among individuals., [Material and Methods]: we identified the genetic and molecular determinants of cardiotoxicity in a simplified model of controlled genetic and phenotypic heterogeneity, generated by a backcross of two mouse strains of divergent phenotypic behavior, FVB and C57BL/6. We evaluated cardiac damage at histopathological level and also quantified different subphenotypes such as signaling pathways associated with cardiac damage and protection, genotoxicity pathways, TGFβ levels, telomere length, and expression of miRNAs in the myocardium., [Results]: We quantified anthracycline cardiotoxicity in a heterogeneous cohort of mice with breast cancer generated by a backcross. Cardiotoxicity was higher in old mice, was higher in the combined treatment with taxanes, was higher in the subendocardial zone and was influenced by the genetic background. We have identified multiple QTL associated with CDA in these different conditions studied. Differences in the grade of anthracycline cardiotoxicity at the histopathological level were accompanied by differences in the molecular levels in the myocardium of different molecular components of the pathways of response to damage at DNA, signaling pathways, miRNAs and telomere length. QTLs associated with these subphenotypes help to define CDA variability. Lastly, we have also defined CDA by multivariate models., [Conclusion]: The identification of genetic and molecular factors responsible for the increased risk of CDA will contribute to a better understanding of their pathophysiology, which could lead to new approaches to predict, prevent and treat this serious complication of chemotherapy., JPL was partially supported by FEDER and the MICINN (SAF2014-56989-R, SAF2017-88854R), the Instituto de Salud Carlos III (PIE14/00066), “Proyectos Integrados IBSAL 2015” (IBY15/00003), the Sandra Ibarra Foundation “de Solidaridad Frente al Cáncer” Foundation and “We can be heroes” Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practice.

  • Cañueto, Javier
  • Burguillo, Javier
  • Moyano-Bueno, David
  • Viñolas-Cuadros, Alex
  • Conde-Ferreirós, Alberto
  • Corchete, Luis A.
  • Pérez-Losada, J.
  • Román-Curto, Concépción
  • Román-Curto, Concépción
[Background]: The new eighth edition of the American Joint Committee on Cancer staging system (AJCC-8) incorporates changes regarding cutaneous squamous cell carcinoma (CSCC)., [Objectives]: We aimed to compare the AJCC-8 staging system with the previous seventh edition of the AJCC staging system (AJCC-7) and the Brigham and Women's Hospital (BWH) alternative staging system to identify their usefulness and the utility of their risk factors in defining prognostic groups in CSCC., [Methods]: A series of 186 CSCCs of the head and neck were retrospectively collected. All 3 staging systems were compared from the standpoint of their ability to predict poor prognosis. Binary logistic regression models were built to determine which risk factors were most relevant., [Results]: Poor prognosis was mainly associated with stage T2 of the AJCC-7, with stages T2b/T3 of the BWH system, and with stage T3 of the AJCC-8. The AJCC-8 and the BWH staging systems displayed overlap with each another in predicting poor prognosis, and both were superior to the AJCC-7. The new risk factors incorporated into the AJCC-8 and the poor degree of differentiation were independently associated with poor outcome., Dr Cañueto is partially supported by a grant (GRS 1342/A/16) from the Regional Health Office of Castile and Leon and by the program INT/M/16/17 from the Regional Health Office of Castile and Leon. Dr Pérez-Losada was partially supported by FEDER and the MICINN (grants SAF2014-56989-R and SAF2017-88854-R), the Instituto de Salud Carlos III (PIE14/00066), and the We Can Be Heroes Foundation
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression

  • Blanco-Gómez, Adrián
  • Hontecillas-Prieto, Lourdes
  • Corchado Cobos, Roberto
  • García-Sancha, Natalia
  • Salvador, Nélida
  • Castellanos-Martín, Andrés
  • Sáez-Freire, María del Mar
  • Mendiburu-Eliçabe, Marina
  • Alonso-López, D.
  • Rivas, Javier de las
  • Lorente, Mar
  • García-Casas, Ana
  • Carmen, Sofía del
  • Abad-Hernández, María del Mar
  • Cruz, Juan Jesús
  • Rodríguez-Sánchez, César Augusto
  • Claros-Ampuero, Juncal
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Orimo, Akira
  • Gridley, Thomas
  • Pérez-Losada, J.
  • Castillo, Sonia
SNAI2 overexpression appears to be associated with poor prognosis in breast cancer, yet it remains unclear in which breast cancer subtypes this occurs. Here we show that excess SNAI2 is associated with a poor prognosis of luminal B HER2+/ERBB2+ breast cancers in which SNAI2 expression in the stroma but not the epithelium correlates with tumor proliferation. To determine how stromal SNAI2 might influence HER2+ tumor behavior, Snai2-deficient mice were crossed with a mouse line carrying the ErbB2/Neu protooncogene to generate HER2+/ERBB2+ breast cancer. Tumors generated in this model expressed SNAI2 in the stroma but not the epithelium, allowing for the role of stromal SNAI2 to be studied without interference from the epithelial compartment. The absence of SNAI2 in the stroma of HER2+/ERBB2+ tumors is associated with: (i) lower levels of cyclin D1 (CCND1) and reduced tumor epithelium proliferation; (ii) higher levels of AKT and a lower incidence of metastasis; (iii) lower levels of angiopoietin-2 (ANGPT2), and more necrosis. Together, these results indicate that the loss of SNAI2 in cancer-associated fibroblasts limits the production of some cytokines, which influences AKT/ERK tumor signaling and subsequent proliferative and metastatic capacity of ERBB2+ breast cancer cells. Accordingly, SNAI2 expression in the stroma enhanced the tumorigenicity of luminal B HER2+/ERBB2+ breast cancers. This work emphasizes the importance of stromal SNAI2 in breast cancer progression and patients' prognosis., S. Castillo-Lluva was the recipient of a Ramón y Cajal research contract from the Spanish Ministry of Economy and Competitiveness (Ministerio de Economía y Competitividad; MINECO), and the work was supported by a MINECO/FEDER research grant (SAF2015-64499-R; RTI2018-094130-B-100). N. García-Sancha was partially supported by the RTI2018-094130-B-100 budget. J. Pérez-Losada was partially supported by FEDER funds, the Carlos III Health Institute (PIE14/00066), MINECO (SAF2014-56989-R, SAF2017-88854R), Castile and León (CSI234P18), the Sandra Ibarra Foundation for Solidarity against Cancer and the “We can be heroes” Foundation. N. García-Sancha is a recipient of an FPU fellowship (MINECO/FEDER). R. Corchado-Cobos, M.d.M. Sáez-Freire, and A. Blanco-Gómez were funded by fellowships from the Spanish Regional Government of Castile and León. The development of the Snai2 KO mice was supported by NIH grant R01HD034883 (to T. Gridley)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Datasets related to a study aimed to identify genetic markers of CDA by subphenotypes associated with cardiotoxicity

  • Gómez-Vecino, Aurora
  • Corchado Cobos, Roberto
  • Blanco-Gómez, Adrián
  • Castillo, Sonia
  • García-Sancha, Natalia
  • Martin-Garcia, Ana
  • Prieto, Carlos
  • Ruiz-Pinto, Sara
  • Pita, Guillermo
  • Velasco-Ruiz, Alejandro
  • Patino-Alonso, María Carmen
  • Galindo-Villardón, Purificación
  • Linarejos Vera-Pedrosa, María
  • Jalife, José
  • Macías de Plasencia, Guillermo
  • Castellanos-Martín, Andrés
  • Sáez-Freire, María del Mar
  • Mendiburu-Eliçabe, Marina
  • Fraile, Susana
  • Rodrigues Teixeira, Telmo
  • García-Macías, Carmen
  • Galvis-Jiménez, Julie Milena
  • García-Sánchez, Asunción
  • Isidoro-García, María
  • Fuentes, Manuel
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • García, Juan L.
  • Hernández-García, María Ángeles
  • Cruz, Juan Jesús
  • Rodríguez-Sánchez, César Augusto
  • Martín-Ruiz, Alejandro
  • Pérez-López, Estefanía
  • Pérez-Martínez, Antonio
  • Gutiérrez-Larraya, Federico
  • Cartón, Antonio J.
  • García-Saenz, José Ángel
  • Patiño-García, Ana
  • Martín, Miguel A.
  • Alonso Gordoa, Teresa
  • Vulsteke, Christof
  • Croes, Lieselot
  • Hatse, Sigrid
  • Van Brussel, Thomas
  • Lambrechts, Diether
  • Wildiers, Hans
  • Holgado-Madruga, Marina
  • González-Neira, Ana
  • Sánchez, Pedro L.
  • Pérez-Losada, J.
Who produced the data? The data has been created by the authors listed above. Is the title specific enough? "Datasets related to a study aimed to identify genetic markers of CDA by subphenotypes associated with cardiotoxicity." Why has the data been created? These datasets are supplementary material with which the principal and supplementary figures and tables of our indicated work were generated. What limitations do the data have (for example, sensitive data has been deleted)? All confidential patient information is not present. We have not had access to that information, following current legal regulations. How should the data be interpreted? These data sets should not be separated from the main article in which they were utilized. Thus, to better understand their context, researchers should see them in the global scenario of our work. Are there gaps in the data, or do they give a complete picture of the topic studied? As indicated above, data should be considered and interpreted in the global context of our study. What processes have generated the data? The processes that generated the data are indicated in the summary of the data above and individually for each of them. Thus, each dataset is accompanied by a legend within the document. What does the data measure in the columns of the files? As indicated, each dataset individually shows the information contained in the legend of each dataset. What software is required to be able to read the data? The datasets are in Excel format. How should the data be quoted? Researchers should cite the data in the context of the work they belong to once it is published and free of the embargo. Can the data be reused? What use licenses are assigned to you? In principle, yes. If additional clinical information is required, these data were previously published by some of us, and the references are included in our manuscript. These data are available from the principal investigators of the references listed in our work upon reasonable request. Are there more versions of the data? Where? I do not think so beyond our files and copies. Have the technical terms and acronyms referenced by the data been defined? A legend with the appropriate descriptions accompanies each dataset. Have the geographic and chronological parameters of the data been qualified? The authors of the work have generated the data. Elsewhere, we indicate the authors of the work, their contributions, and affiliations. Are keywords sufficiently data-specific? Are they based on any thesaurus? Keywords are based on our study. We include cardiotoxicity due to anthracyclines, missing heritability, subphenotype, pathophenotype, complex trait. What is the name of the research project in which the data are framed? The main research project in which the data is prepared is: Títle: "Chemotherapy cardiotoxicity in the elderly: a translational and personnel approach." Ref.: PIE14/00066 Who has financed data production and management? Each of the authors of the study has its funding. The grants are included in the acknowledgments section of our manuscript., The data were created over the last six years during the achievement of this project., Here we present a series of supplemental datasets that complement our study entitled "A Systems Genetics approach to identify genetic markers of cardiotoxicity due to anthracyclines in cancer patients." The datasets presented here were used to generate the main and supplementary figures and tables of the indicated study. The study consists of the identification of genetic markers of cardiotoxicity due to anthracyclines (CDA). CDA is a complex genesis disease or complex trait, and because of this, there is a component of missing heritability. Therefore, it is not possible to identify genetic markers associated with CDA risk. Here, we propose that molecular subphenotypes associated with the CDA may be a strategy for identifying some of this missing heritability and risk markers associated with it. A similar strategy could be applied to identify markers of other diseases of complex genesis. This study is done using a genetically heterogeneous cohort of mice that developed breast cancer and was treated with doxorubicin or a combined treatment of doxorubicin and docetaxel. The mouse cohort was generated by backcrossing, so each mouse is genetically unique. Post-chemotherapy heart damage was assessed by quantifying fibrosis's cardiac area and the thickness of myocardial fibers. The genetic regions associated with CDA were assessed by massive genotyping and genetic linkage analysis. Several molecular subphenotypes were quantified in the myocardium, and their association with the CDA was evaluated. Subsequently, we identified which of them were most statistically associated with CDA in multivariate models. Moreover, which complex trait loci (QTLs) associated with molecular subphenotypes best explained CDA. This strategy served to identify in the cohort of mice genes whose allelic forms could be candidates for the risk of CDA. Allelic variants of these genes were evaluated in four cohorts of cancer patients treated with anthracyclines and whose CDA was evaluated by echocardiography or cardiac magnetic resonance imaging (CMR)., JPL laboratory was partially supported by the European Regional Development Fund (ERDF) and the Ministry of Science, Innovation, and Universities (SAF2014-56989-R, SAF2017-88854R), the Carlos III Health Institute (PIE14/00066), "Proyectos Integrados IBSAL 2015" (IBY15/00003), the Regional Government of Castile and Leon (CSI234P18), and "We can be heroes" Foundation. AGN laboratory and human patients' study are supported by funds from the ISCIII project grant (PI18/01242). The Human Genotyping unit is a member of CeGen, PRB3, and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF. SCLL was the recipient of a Ramón y Cajal research contract from the Spanish Ministry of Economy and Competitiveness, and the work was supported by MINECO/FEDER research grants (RTI2018-094130-B-100). The Proteomics Unit belongs to ProteoRed, PRB3-ISCIII, supported by grant PT17/0019/0023, of the PE I + D + I 2017-2020, funded by ISCIII and FEDER. RCC is funded by fellowships from the Spanish Regional Government of Castile and León. NGS is a recipient of an FPU fellowship (MINECO/FEDER). hiPSC-CM studies were funded in part by the "la Caixa" Banking Foundation under the project code HR18-00304" and Severo Ochoa CNIC Intramural Project (Expediente 12-2016 IGP) to JJ., Supplemental Dataset 1: CDA pathophenotypes after doxorubicin treatment. We treated 71 mice carrying breast cancer with doxorubicin. Each mouse was generated by backcrossing; thus, each one is genetically unique. Cardiotoxicity due to anthracyclines (CDA) was evaluated by automatically quantifying the heart fibrosis area and the average area of myocardial fibers as pathophenotypes of cardiotoxicity using the Ariol slide scanner. The histopathological damage was evaluated in the subendocardium and subepicardium from five randomly chosen regions of each sample (averages in μm2 are shown).-- Supplemental Dataset 2: CDA pathophenotypes after the combined therapy. We treated 61 mice carrying breast cancer with the combined therapy with doxorubicin and docetaxel. Each mouse was generated by backcrossing; thus, each one is genetically unique. Cardiotoxicity due to anthracyclines (CDA) was evaluated by automatically quantifying the heart fibrosis area and the average area of myocardial fibers as pathophenotypes of cardiotoxicity using the Ariol slide scanner. The histopathological damage was evaluated in the subendocardium and subepicardium from five randomly chosen regions of each sample (averages in μm2 are shown).-- Supplemental Dataset 3: CDA subphenotypes after doxorubicin therapy. Myocardium molecular subphenotypes after doxorubicin therapy. Proteins were quantified by a multiplex bead array (Luminex). TGFβ units are shown in pg/mL. The rest of the protein levels are shown in molecular fluorescence intensity (MFI) Units. The telomeric length was quantified by QPCR (RQ units). miRNAs were quantified by QPCR (RQ units). QPCR analyses were assessed by the ΔΔCT method; we show the averages of triplicates.-- Supplemental Dataset 4: CDA subphenotypes after the combined therapy. Myocardium molecular subphenotypes after the combined therapy with doxorubicin and docetaxel. Proteins were quantified by a multiplex bead array (Luminex). TGFβ units are shown in pg/mL. The rest of the protein levels are shown in molecular fluorescence intensity (MFI) Units. The telomeric length was quantified by QPCR (RQ units). miRNAs were quantified by QPCR (RQ units). QPCR analyses were assessed by the ΔΔCT method; we show the averages of triplicates.-- Supplemental Dataset 5: Correlations identified between molecular subphenotype levels in the myocardium and pathophenotypes of cardiotoxicity due to anthracyclines (CDA) after doxorubicin therapy in all mice.-- Supplemental Dataset 6: Correlations identified between molecular subphenotype levels in the myocardium and pathophenotypes of cardiotoxicity due to anthracyclines (CDA) after doxorubicin therapy in young mice. Correlation of Spearman.-- Supplemental Dataset 7: Correlations identified between molecular subphenotype levels in the myocardium and pathophenotypes of cardiotoxicity due to anthracyclines (CDA) after doxorubicin therapy in old mice. Correlation of Spearman.-- Supplemental Dataset 8: Correlations identified between molecular subphenotype levels in the myocardium and pathophenotypes of cardiotoxicity due to anthracyclines (CDA) after the combined therapy in all mice. Correlation of Spearman.-- Supplemental Dataset 9: Correlations identified between molecular subphenotype levels in the myocardium and pathophenotypes of cardiotoxicity due to anthracyclines (CDA) after the combined therapy in young mice. Correlation of Spearman.-- Supplemental Dataset 10: Correlations identified between molecular subphenotype levels in the myocardium and pathophenotypes of cardiotoxicity due to anthracyclines (CDA) after the combined therapy in old mice. Correlation of Spearman.-- Supplemental Dataset 11: Linkage analysis of molecular subphenotype levels quantified in the myocardium. Lod scores after doxorubicin therapy in all mice. The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution. Linkage analysis was carried out using interval mapping with the expectation-maximization (EM) algorithm and R/QTL software. The criteria for significant and suggestive linkages for single markers were chosen based on Lander and Kruglyak (see methods section of our manuscript).-- Supplemental Dataset 12: Linkage analysis of molecular subphenotype levels quantified in the myocardium. Lod scores after doxorubicin therapy in young mice. The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution. Linkage analysis was carried out using interval mapping with the expectation-maximization (EM) algorithm and R/QTL software. The criteria for significant and suggestive linkages for single markers were chosen based on Lander and Kruglyak (see methods section of our manuscript).-- Supplemental Dataset 13: Linkage analysis of molecular subphenotype levels quantified in the myocardium. Lod scores after doxorubicin therapy in old mice. The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution. Linkage analysis was carried out using interval mapping with the expectation-maximization (EM) algorithm and R/QTL software. The criteria for significant and suggestive linkages for single markers were chosen based on Lander and Kruglyak (see methods section of our manuscript).-- Supplemental Dataset 14: Linkage analysis of molecular subphenotype levels quantified in the myocardium. Lod scores after the combined therapy in all mice. The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution. Linkage analysis was carried out using interval mapping with the expectation-maximization (EM) algorithm and R/QTL software. The criteria for significant and suggestive linkages for single markers were chosen based on Lander and Kruglyak (see methods section of our manuscript).-- Supplemental Dataset 15: Linkage analysis of molecular subphenotype levels quantified in the myocardium. Lod scores after the combined therapy in young mice. The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution. Linkage analysis was carried out using interval mapping with the expectation-maximization (EM) algorithm and R/QTL software. The criteria for significant and suggestive linkages for single markers were chosen based on Lander and Kruglyak (see methods section of our manuscript).-- Supplemental Dataset 16: Linkage analysis of molecular subphenotype levels quantified in the myocardium. Lod scores after the combined therapy in old mice. The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution. Linkage analysis was carried out using interval mapping with the expectation-maximization (EM) algorithm and R/QTL software. The criteria for significant and suggestive linkages for single markers were chosen based on Lander and Kruglyak (see methods section of our manuscript).-- Supplemental Dataset 17: Massive genotyping of mouse cohort treated with doxorubicin. The genome-wide scan was carried out at the Spanish National Centre of Genotyping (CeGEN) at the Spanish National Cancer Research Centre (CNIO, Madrid, Spain). The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution.-- Supplemental Dataset 18: Massive genotyping of mouse cohort treated with the combined therapy. The genome-wide scan was carried out at the Spanish National Centre of Genotyping (CeGEN) at the Spanish National Cancer Research Centre (CNIO, Madrid, Spain). The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution.-- Supplemental Dataset 19: Linkage analysis of CDA pathophenotypes quantified in the myocardium. Lod scores after doxorubicin therapy in all mice. The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution. Linkage analysis was carried out using interval mapping with the expectation-maximization (EM) algorithm and R/QTL software. The criteria for significant and suggestive linkages for single markers were chosen based on Lander and Kruglyak (see methods section of our manuscript).-- Supplemental Dataset 20: Linkage analysis of CDA pathophenotypes quantified in the myocardium. Lod scores after doxorubicin therapy in young mice. The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution. Linkage analysis was carried out using interval mapping with the expectation-maximization (EM) algorithm and R/QTL software. The criteria for significant and suggestive linkages for single markers were chosen based on Lander and Kruglyak (see methods section of our manuscript).-- Supplemental Dataset 21: Linkage analysis of CDA pathophenotypes quantified in the myocardium. Lod scores after doxorubicin therapy in old mice. The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution. Linkage analysis was carried out using interval mapping with the expectation-maximization (EM) algorithm and R/QTL software. The criteria for significant and suggestive linkages for single markers were chosen based on Lander and Kruglyak (see methods section of our manuscript).-- Supplemental Dataset 22: Linkage analysis of CDA pathophenotypes quantified in the myocardium. Lod scores after the combined therapy in all mice. The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution. Linkage analysis was carried out using interval mapping with the expectation-maximization (EM) algorithm and R/QTL software. The criteria for significant and suggestive linkages for single markers were chosen based on Lander and Kruglyak (see methods section of our manuscript).-- Supplemental Dataset 23: Linkage analysis of CDA pathophenotypes quantified in the myocardium. Lod scores after the combined therapy in young mice. The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution. Linkage analysis was carried out using interval mapping with the expectation-maximization (EM) algorithm and R/QTL software. The criteria for significant and suggestive linkages for single markers were chosen based on Lander and Kruglyak (see methods section of our manuscript).-- Supplemental Dataset 24: Linkage analysis of CDA pathophenotypes quantified in the myocardium. Lod scores after the combined therapy in old mice. The Illumina Mouse Medium Density Linkage Panel Assay was used to genotype 130 F1BX mice at 1449 single nucleotide polymorphisms (SNPs). Genotypes were classified as FVB/FVB (F/F) or FVB/C57BL/6 (F/B). Ultimately, 806 SNPs are informative from the FVB and C57BL/6 mice; the average genomic distance between these SNPs was 9.9 Mb. The genotype proportion among the F1BX mice showed a normal distribution. Linkage analysis was carried out using interval mapping with the expectation-maximization (EM) algorithm and R/QTL software. The criteria for significant and suggestive linkages for single markers were chosen based on Lander and Kruglyak (see methods section of our manuscript).-- Supplemental Dataset 25: Human breast cancer cohort-1 genotyping. The association of genetic variants with CDA was evaluated in four patient cohorts previously published by some of us. Here, 53 anthracycline-treated breast cancer patients (Breast Cancer cohort-1) [Ruiz-Pinto et al., Breast Cancer Res Treat., 2018], the cardiac function was assessed by echocardiography to evaluate the left ventricular ejection fraction (LVEF). SNVs were detected on the Infinium™ Global Screening Array-24 v2.0 BeadChip. Data were imputed using the Michigan Imputation Server with Minimac4 [Das et al., Nature Genetics 2016]; after retrieving the data, all markers with R2 < 0.7 were removed from the analysis before proceeding further. SNVs related to candidate genes identified in the mouse cohort were evaluated.-- Supplemental Dataset 26: Genes and genetic markers that were chosen to be evaluated in the breast cancer cohort-1 for the case and control assessment and also for CDA as a continuous variable. The chosen human genetic markers belong to allelic forms of candidate genes identified in the backcross mouse cohort associated with CDA risk variation.-- Supplemental Dataset 27: Human breast cancer cohort-1 and CDA evaluation through the Left Ventricular Ejection Fraction (LVEF) determined by echocardiography. LVEF values are shown before chemotherapy (LVEF-1), at first follow-up after treatment was completed (LVEF-2), and the increment of LVEF (difference between LVEF- 1 and LVEF-2). These values were used to evaluate CDA risk as a continuous variable.-- Supplemental Dataset 28: Human breast cancer cohort-2 genotyping. The association of genetic variants with CDA was evaluated in four patient cohorts previously published by some of us. Here, 420 anthracycline-treated breast cancer patients (Breast Cancer cohort-2) [Vulsteke et al., Breast Cancer Res Treat, 2015], the cardiac function was assessed by echocardiography to evaluate the left ventricular ejection fraction (LVEF). SNVs were detected on the Infinium™ Global Screening Array-24 v2.0 BeadChip. Data were imputed using the Michigan Imputation Server with Minimac4 [Das et al., Nature Genetics, 2016]; after retrieving the data, all markers with R2 < 0.7 were removed from the analysis before proceeding further. SNVs related to candidate genes identified in the mouse cohort were evaluated.-- Supplemental Dataset 29: Genes and genetic markers that were chosen to be evaluated in the breast cancer cohort-2 for the case and control assessment and also for CDA as a continuous variable. The chosen human genetic markers belong to allelic forms of candidate genes identified in the backcross mouse cohort associated with CDA risk variation.-- Supplemental Dataset 30: Human breast cancer cohort-2 and CDA evaluation through the Left Ventricular Ejection Fraction (LVEF) determined by echocardiography. LVEF values are shown before chemotherapy (LVEF-1), at first follow-up after treatment was completed (LVEF-2), and the increment of LVEF (difference between LVEF- 1 and LVEF-2). These values were used to evaluate CDA risk as a continuous variable.-- Supplemental Dataset 31: Pediatric cancer cohort genotyping. The association of genetic variants with CDA was evaluated in four patient cohorts previously published by some of us. Here, 71 anthracycline-treated pediatric cancer patients (Pediatric cohort) [Ruiz-Pinto et al., Pharmacogenetics Genomics, 2017], the cardiac function was assessed by echocardiography to evaluate the left ventricular fractional shortening (LVFS). SNVs were detected on the Infinium™ Global Screening Array-24 v2.0 BeadChip. Data were imputed using the Michigan Imputation Server with Minimac4 [Dast et al., Nature Genetics 2016]; after retrieving the data, all markers with R2 < 0.7 were removed from the analysis before proceeding further. SNVs related to candidate genes identified in the mouse cohort were evaluated.-- Supplemental Dataset 32: Genes and genetic markers that were chosen to be evaluated in the pediatric cohort for the case and control assessment and also for CDA as a continuous variable. The chosen human genetic markers belong to allelic forms of candidate genes identified in the backcross mouse cohort associated with CDA risk variation.-- Supplemental Dataset 33: Pediatric cohort and CDA evaluation through the Left Ventricular Fractional Shortening (LVFS) determined by echocardiography. LVEF values are shown before chemotherapy (LVEF-1), at first follow-up after treatment was completed (LVEF-2), and the increment of LVEF (difference between LVEF- 1 and LVEF-2). These values were used to evaluate CDA risk as a continuous variable.-- Supplemental Dataset 34: Human cancer Cardiac Magnetic Resonance (CMR) cohort genotyping. The association of genetic variants with CDA was evaluated in four patient cohorts previously published by some of us. Cardiac Magnetic Resonance (CMR) was carried out in 24 cancer patients (CMR cohort) [Barreiro-Pérez et al., Rev Esp Cardiol, 2018]. CMR was carried out at baseline and after every two cycles of a regular course of anthracycline therapy.-- Supplemental Dataset 35: Genes and genetic markers that were chosen to be evaluated in the CMR cancer cohort for the case and control assessment and also for CDA as a continuous variable. The chosen human genetic markers belong to allelic forms of candidate genes identified in the backcross mouse cohort associated with CDA risk variation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy

  • Xiao, Yi
  • Yin, Chunli
  • Wang, Yuli
  • Lv, Hanlin
  • Wang, Wenqing
  • Huang, Yurong
  • Pérez-Losada, J.
  • Snijders, Antoine M.
  • Mao, Jian-Hua
  • Zhang, Pengju
© 2018 The Authors., Gefitinib, an epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI), is an effective treatment for non-small-cell lung cancer (NSCLC) with EGFR activating mutations, but inevitably, the clinical efficacy is impeded by the emergence of acquired resistance. The tumor suppressor gene FBXW7 modulates chemosensitivity in various human cancers. However, its role in EGFR-TKI therapy in NSCLC has not been well studied. Here, we demonstrate that the mice with deficient Fbxw7 have greater susceptibility to urethane-induced lung tumor development. Through analysis of The Cancer Genome Atlas data, we show that deletion of FBXW7 occurs in 30.9% of lung adenocarcinomas and 63.5% of lung squamous cell carcinomas, which significantly leads to decrease in FBXW7 mRNA expression. The reduction in FBXW7 mRNA level is associated with poor overall survival in lung cancer patients. FBXW7 knockdown dramatically promotes epithelial–mesenchymal transition, migration, and invasion in NSCLC cells. Moreover, with silenced FBXW7, EGFR-TKI-sensitive cells become resistant to gefitinib, which is reversed by the mammalian target of rapamycin inhibitor, rapamycin. Furthermore, xenograft mouse model studies show that FBXW7 knockdown enhances tumorigenesis and resistance to gefitinib. Combination of gefitinib with rapamycin treatment suppresses tumor formation of gefitinib-resistant (GR) FBXW7-knockdown cells. In conclusion, our findings suggest that loss of FBXW7 promotes NSCLC progression as well as gefitinib resistance and combination of gefitinib and rapamycin may provide an effective therapy for GR NSCLC., This work was supported by National Natural Science Foundation of China (Nos 81672858, 81470127); by the Natural Science Foundation of Shandong province (No. ZR2014HM032) (to PZ), and Lawrence Berkeley National Laboratory Directed Research and Development (LDRD) program funding under contract DE AC02-05CH11231 (to AMS and JHM); and by FEDER and the MICINN (SAF2014-56989-R, SAF2017-88854R), and the Instituto de Salud Carlos III (PIE14/00066) and ‘We can be heroes’ Foundation (to JPL)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rapid growth rate is associated with poor prognosis in cutaneous squamous cell carcinoma

  • Cañueto, Javier
  • Martin-Vallejo, Javier
  • Cardeñoso-Álvarez, Ester
  • Fernández-López, Emilia
  • Pérez-Losada, J.
  • Román-Curto, Concépción
[Background]: Cutaneous squamous cell carcinoma (cSCC) represents the most common form of skin cancer after basal cell carcinoma, and can be both locally invasive and metastatic to distant sites. Growth rate (GR) has been poorly evaluated in cSCC, despite clinical evidence suggesting that GR is an important risk factor in cSCC., [Aim]: To analyse the influence of GR in cSCC prognosis., [Methods]: We retrospectively evaluated GR in a series of 90 cSCCs and tried to correlate GR with prognosis in cSCC., [Results]: We demonstrated that tumours with a GR of > 4 mm/month exhibit a higher risk of nodal progression and a shorter progression time to lymph node metastasis in cSCC than those with GR of < 4 mm/month. As expected, GR correlated with tumour proliferation, as determined by Ki-67 expression., [Conclusions]: We consider a GR of 4 mm/month as the cutoff point that distinguishes between rapid- and slow-progressing tumours and, more importantly, to identify a subset of high-risk cSCCs., JC was partially supported by Gerencia Regional de Salud, Junta de Castilla y León (GRS 1342/A/16) and by the programme INT/M/16/17. JPL was partially supported by FEDER and MICINN (SAF2014–56989-R), Instituto de Salud Carlos III (PIE14/00066), Junta de Castilla y León (BIO/SA31/15, CSI001416), IBSAL (IBY15/00003), the Eugenio Rodríguez Pascual, the Fundación Sandra Ibarra de Solidaridad frente al Cáncer and We can be Heroes Foundation. CR-C is funded by Q3718001E (2009–2010) and GRS 612/A/11 (2011–2012) and the Fundación Eugenio Rodríguez Pascual.